

Nick D Tsihlis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2590856/publications.pdf>

Version: 2024-02-01

34
papers

728
citations

687363

13
h-index

526287

27
g-index

36
all docs

36
docs citations

36
times ranked

1016
citing authors

#	ARTICLE	IF	CITATIONS
1	Nitric oxide and nanotechnology: A novel approach to inhibit neointimal hyperplasia. <i>Journal of Vascular Surgery</i> , 2008, 47, 173-182.	1.1	122
2	The role of nitric oxide in the pathophysiology of intimal hyperplasia. <i>Journal of Vascular Surgery</i> , 2007, 45, A64-A73.	1.1	89
3	Tissue-Factor Targeted Peptide Amphiphile Nanofibers as an Injectable Therapy To Control Hemorrhage. <i>ACS Nano</i> , 2016, 10, 899-909.	14.6	72
4	Nitric Oxide Inhibits Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia by Increasing the Ubiquitination and Degradation of UbcH10. <i>Cell Biochemistry and Biophysics</i> , 2011, 60, 89-97.	1.8	67
5	Isopropylamine NONOate (IPA/NO) moderates neointimal hyperplasia following vascular injury. <i>Journal of Vascular Surgery</i> , 2010, 51, 1248-1259.	1.1	52
6	Basic Science Review: Nitric Oxide-Releasing Prosthetic Materials. <i>Vascular and Endovascular Surgery</i> , 2009, 43, 121-131.	0.7	39
7	Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 295, H2388-H2398.	3.2	31
8	Peptide Amphiphile Supramolecular Nanostructures as a Targeted Therapy for Atherosclerosis. <i>Macromolecular Bioscience</i> , 2019, 19, e1900066.	4.1	29
9	Development of Optimized Tissue-Factor-Targeted Peptide Amphiphile Nanofibers to Slow Noncompressible Torso Hemorrhage. <i>ACS Nano</i> , 2020, 14, 6649-6662.	14.6	28
10	Atheroma Niche-Responsive Nanocarriers for Immunotherapeutic Delivery. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801545.	7.6	26
11	Surface salt bridges modulate the DNA site size of bacterial histone-like HU proteins. <i>Biochemical Journal</i> , 2005, 390, 49-55.	3.7	25
12	Nitric oxide delivery via a permeable balloon catheter inhibits neointimal growth after arterial injury. <i>Journal of Surgical Research</i> , 2013, 180, 35-42.	1.6	17
13	Nitric oxide decreases activity and levels of the 11S proteasome activator PA28 in the vasculature. <i>Nitric Oxide - Biology and Chemistry</i> , 2012, 27, 50-58.	2.7	15
14	Development of Poly(1,8-octanediol-co-citrate-co-ascorbate) Elastomers with Enhanced Ascorbate Performance for Use as a Graft Coating to Prevent Neointimal Hyperplasia. <i>ACS Applied Bio Materials</i> , 2020, 3, 2150-2159.	4.6	13
15	Emerging Therapies for Prehospital Control of Hemorrhage. <i>Journal of Surgical Research</i> , 2020, 248, 182-190.	1.6	11
16	Intravenous Delivery of Lung-Targeted Nanofibers for Pulmonary Hypertension in Mice. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100302.	7.6	10
17	Pharmacokinetics and biodistribution of a collagen-targeted peptide amphiphile for cardiovascular applications. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00672.	2.4	7
18	Development of Fractalkine-Targeted Nanofibers that Localize to Sites of Arterial Injury. <i>Nanomaterials</i> , 2020, 10, 420.	4.1	7

#	ARTICLE	IF	CITATIONS
19	Emerging therapies for smoke inhalation injury: a review. <i>Journal of Translational Medicine</i> , 2020, 18, 141.	4.4	7
20	Coating small-diameter ePTFE vascular grafts with tunable poly(diol-co-citrate-co-ascorbate) elastomers to reduce neointimal hyperplasia. <i>Biomaterials Science</i> , 2021, 9, 5160-5174.	5.4	7
21	Nitric Oxide Increases Lysine 48-Linked Ubiquitination Following Arterial Injury. <i>Journal of Surgical Research</i> , 2011, 170, e169-e177.	1.6	6
22	A comparative study of a preclinical survival model of smoke inhalation injury in mice and rats. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 319, L471-L480.	2.9	6
23	Self-Assembled Peptide Amphiphile Nanofibers for Controlled Therapeutic Delivery to the Atherosclerotic Niche. <i>Advanced Therapeutics</i> , 2021, 4, 2100103.	3.2	6
24	Peptide Amphiphile Supramolecular Nanofibers Designed to Target Abdominal Aortic Aneurysms. <i>ACS Nano</i> , 2022, 16, 7309-7322.	14.6	6
25	Emerging antenatal therapies for congenital diaphragmatic hernia-induced pulmonary hypertension in preclinical models. <i>Pediatric Research</i> , 2021, 89, 1641-1649.	2.3	5
26	Development of novel nanofibers targeted to smoke-injured lungs. <i>Biomaterials</i> , 2021, 274, 120862.	11.4	5
27	The <i>Saccharomyces cerevisiae</i> RNA polymerase III recruitment factor subunits Brf1 and Bdp1 impose a strict sequence preference for the downstream half of the TATA box. <i>Nucleic Acids Research</i> , 2006, 34, 5585-5593.	14.5	4
28	Nitric oxide is less effective at inhibiting neointimal hyperplasia in spontaneously hypertensive rats. <i>Nitric Oxide - Biology and Chemistry</i> , 2013, 35, 165-174.	2.7	4
29	Nitric oxide may inhibit neointimal hyperplasia by decreasing isopeptidase T levels and activity in the vasculature. <i>Journal of Vascular Surgery</i> , 2013, 58, 179-186.	1.1	3
30	Nitric oxide differentially affects proteasome activator 28 after arterial injury in type 1 and type 2 diabetic rats. <i>Journal of Surgical Research</i> , 2016, 202, 413-421.	1.6	2
31	Nitric oxide affects UbcH10 levels differently in type 1 and type 2 diabetic rats. <i>Journal of Surgical Research</i> , 2015, 196, 180-189.	1.6	1
32	Systemic Delivery of a Novel Fractalkine Binding Peptide Amphiphile Nanofiber to Target Injured Vasculature. <i>Journal of the American College of Surgeons</i> , 2018, 227, S296-S297.	0.5	0
33	Evaluation of a Targeted Drug-Eluting Intravascular Nanotherapy to Prevent Neointimal Hyperplasia in an Atherosclerotic Rat Model. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2000093.	3.6	0
34	Anti-proliferative properties of IPA/NO: a novel use of an HNO-eluting compound. <i>FASEB Journal</i> , 2007, 21, A1129.	0.5	0